Receive Discount Codes straight to your inbox!* (Conditions apply)

Discount code Subs form

By logging in or enrolling, you agree to have read our Privacy Policy and Ts & Cs, and to receive weekly email updates with new course content, materials, and valuable learning resources. Feel free to call or text us at 0432 894 232 for any assistance.

Chapter 1 · Cardiovascular Medicine · Lesson 1

Absolute cardiovascular risk assessment and hypertension

Fellowship-level theory for the RACGP AKT and KFP, built on current Australian guidelines.

Next scheduled review: November 2027 Reading time ≈ 60 min
⚠ Guideline watch — read this first

The current Australian hypertension guideline is still the Heart Foundation 2016 guideline. A replacement, the draft 2027 Australian Guideline for elevated blood pressure and hypertension in adults (Heart Foundation, Stroke Foundation and Hypertension Australia), was released for public consultation on 24 September 2026 and closed on 12 October 2026. It has not yet been finalised.4

Exam questions are written against published guidance. Learn the 2016 definitions and targets below, but expect thresholds and targets to change when the final guideline is published. This lesson will be updated when that happens.

What has changed recently
  • 24 Sep – 12 Oct 2026: draft 2027 Australian hypertension guideline released for consultation; not yet final (see Guideline watch).
  • 1 Apr 2026: dual single-pill antihypertensive combinations PBS-listed as initial therapy.
  • 2025: Endocrine Society recommends aldosterone:renin ratio screening for all people with hypertension.
  • 2025: Heart Health Check MBS items (699, 177) extended to June 2028.
  • 2023: Aus CVD Risk Calculator replaced the Framingham-based 2012 approach.
⚠ Studying from old notes?

Each statement below was standard teaching a few years ago. Decide whether it is still true before you tap.

High cardiovascular risk means a 5-year risk above 15%.
No longer true. Since 2023, high risk is ≥10%, intermediate 5 to <10%, low <5%. See 2.7.
People with diabetes aged over 60 are automatically high risk.
No longer true. Diabetes is now assessed with the calculator’s diabetes equation. Only established CVD, confirmed FH, eGFR <45 or high uACR are high risk without calculation.
First Nations people should have CVD risk assessed from age 35.
No longer true. The calculator is used from age 30 in First Nations people, with risk factors checked from 18.
Single-pill antihypertensive combinations are PBS-subsidised only after monotherapy has failed.
No longer true. Since 1 April 2026, dual fixed-dose combinations can be prescribed as initial therapy.

Cold-start check

Answer these five questions before you read the lesson. Getting some wrong is the point: attempting questions before studying helps you remember the answers afterwards, and your score tells you where to spend your time. Preparation pays off: in the 2026.2 AKT, 85.9% of first-attempt candidates passed, compared with 62.5% of those sitting a second time.16

1. Under the 2023 Australian guideline, which 5-year CVD risk counts as high?

10% or more. The 15% threshold belongs to the superseded 2012 guideline. Read 2.4 Risk categories and what to do →

2. An adult’s 24-hour ambulatory average is 132/78 mmHg. Does this meet the threshold for hypertension?

Yes. The 24-hour threshold is ≥130/80; any one ABPM threshold exceeded confirms hypertension. Read 3.3 Out-of-clinic measurement and diagnostic thresholds →

3. Which person is high risk without using the calculator?

Sustained eGFR 40. Moderate–severe CKD (eGFR <45 or high uACR) and confirmed FH are the clinically determined high-risk conditions. Read 2.2 High risk without using the calculator →

4. Since April 2026, how can a dual single-pill antihypertensive combination be prescribed on the PBS?

As initial treatment. 30-day packs are unrestricted; 60-day packs require stable disease. Read 3.8 Choosing and stepping up medicines →

5. Which group starts formal CVD risk assessment with the calculator from age 30?

First Nations people (30–79). People with diabetes start at 35; everyone else at 45. Read 2.1 Who to assess, and when →

Your score: / 5

ScoreWhat to do
5 / 5Strong start. Skim the key takeaways, then go straight to the self-check questions.
3–4 / 5Read the sections linked from the questions you missed, then do the self-check.
0–2 / 5Work through the whole lesson. Your notes are probably out of date — check the old-notes box above.

Learning objectives

  1. Identify who needs CVD risk assessment, and at what age.
  2. Recognise people who are high risk without using the calculator.
  3. Apply risk categories, reclassification factors and reassessment intervals.
  4. Measure BP correctly and confirm a diagnosis of hypertension.
  5. Investigate for target-organ damage and secondary causes.
  6. Start, step up and monitor antihypertensive therapy safely.
  7. Recognise hypertensive emergency and resistant hypertension.

How this is examined

  • AKT: calculator eligibility ages, risk thresholds, reassessment intervals, ABPM thresholds, drug adverse effects and interactions, ARR interpretation.
  • KFP: select the most appropriate options from a list — investigations for newly confirmed hypertension, the next step to confirm a diagnosis, first-line drug choice for a given comorbidity, what to stop (NSAID, ACE inhibitor in pregnancy), reclassification factors and when to refer.
  • Common trap: answering from the superseded 2012 absolute risk guideline (Framingham, 15% threshold). See Table 4b.
★ Study-priority stars

Every section carries a GP Institute study-priority rating. It is our editorial judgement, based on the RACGP curriculum, how heavily current Australian guidelines emphasise the topic, patient safety, recent changes, and the themes in published RACGP exam reports. It is not an official RACGP weighting, and any topic can be examined.

RatingWhat it means for your study
★★★★Must know. Core, frequently examined, safety-critical or recently changed. Know it cold, without notes.
★★★☆High yield. Commonly tested; know the thresholds, drugs and next steps.
★★☆☆Know the principles. Understand the reasoning; detailed numbers are less likely to be asked.
★☆☆☆Background. Read once for context.

1. Why it matters ★☆☆☆

Cardiovascular disease (CVD) — coronary heart disease, stroke and peripheral arterial disease — remains one of the leading causes of death and disability in Australia. Most CVD events occur in people who are not at the extreme of any single risk factor. For this reason Australian guidance moved away from treating single numbers (a blood pressure, a cholesterol) and towards treating absolute risk: the probability that a person will have a CVD event over the next five years, given all their risk factors together.

Raised blood pressure is the single most important modifiable contributor. Control rates in Australia are poor: the National Hypertension Taskforce aims to lift national BP control from about 32% to 70% by 2030.8 General practice is where most of that work happens: detecting raised BP, confirming it properly, estimating overall risk, treating, and keeping people on treatment.

Core principle

Treatment intensity should follow absolute risk, not a single risk factor. The same BP of 150/90 may justify medication in a 68-year-old smoker with diabetes and only lifestyle advice in a healthy 46-year-old.

2. Absolute CVD risk assessment ★★★★

The 2023 Australian guideline for assessing and managing cardiovascular disease risk and its Aus CVD Risk Calculator (cvdcheck.org.au) replaced the 2012 Framingham-based approach.1,2 The calculator is built on the New Zealand PREDICT equations, recalibrated for Australia, and estimates 5-year risk of a fatal or non-fatal CVD event.

2.1 Who to assess, and when ★★★☆

The calculator is for primary prevention only — people without known CVD. A person who already has CVD (previous MI, angina, stroke, TIA, peripheral arterial disease, revascularisation) is managed under secondary prevention and is not risk-scored.

↔ Swipe sideways to see the whole figure

Age ranges for using the Aus CVD Risk Calculator by population group 183035457980+ All adults Diabetes First Nations people Calculator 45–79 Calculator 35–79 Risk factors 18–29 Calculator 30–79 Clinical judgement
Figure 1. Age ranges for formal CVD risk assessment with the Aus CVD Risk Calculator (people without known CVD). The calculator is validated to age 79 and probably underestimates risk at 80 and over.2

2.2 High risk without using the calculator ★★★★

Some people are clinically determined to be high risk. Do not run the calculator — manage them as high risk:1,2

Table 1. Clinically determined high CVD risk (2023 guideline)
ConditionCriteria
Established CVDPrevious MI, angina, stroke, TIA, PAD or revascularisation — this is secondary prevention, not a risk calculation
Moderate–severe CKDSustained eGFR <45 mL/min/1.73m² or persistent uACR >25 mg/mmol (men) / >35 mg/mmol (women)
Familial hypercholesterolaemiaConfirmed diagnosis (clinical criteria or genetic testing)
Exam pearl

Diabetes is no longer automatically high risk. Under the 2012 guideline, diabetes plus age >60 or microalbuminuria meant automatic high risk. In 2023, people with diabetes are assessed with the calculator, which has a diabetes-specific equation using HbA1c, time since diagnosis, eGFR, uACR, BMI and insulin use.2

2.3 What the calculator needs ★★☆☆

Table 2. Aus CVD Risk Calculator inputs
GroupInputs
Core (everyone)Age, sex, smoking status, diabetes status, systolic BP, total cholesterol and HDL-C (TC:HDL ratio), use of BP-lowering, lipid-lowering and antithrombotic medicines, atrial fibrillation
OptionalPostcode (area-level socioeconomic deprivation)
Diabetes equationTime since diagnosis, HbA1c, eGFR, uACR, BMI, insulin use in the past 6 months

Practical points: use the average of two or more BP readings; use a fasting or non-fasting lipid profile; record current treatment accurately, because the equation accounts for it.

2.4 Risk categories and what to do ★★★★

↔ Swipe sideways to see the whole figure

Five-year CVD risk categories: low under 5 percent, intermediate 5 to under 10 percent, high 10 percent or more LOWINTERMEDIATEHIGH 0%5%10%5-year risk LifestyleReassess in 5 years Lifestyle + consider drugsReassess in 2 years (if untreated) Lifestyle + BP-lowering + lipid-loweringFormal reassessment not needed
Figure 2. 2023 risk categories (estimated 5-year risk of a CVD event) and the default management for each.1
Table 3. Management by risk category
CategoryLifestyleMedicinesReassess
HIGH ≥10%Yes — intensive, repeated supportPrescribe BP-lowering and lipid-modifying therapy after discussing benefits and harms, unless contraindicatedFormal reassessment generally not needed; manage according to clinical context
INTERMEDIATE 5 to <10%YesConsider BP-lowering and lipid-modifying therapy through shared decision-makingEvery 2 years if not on medicines; sooner if close to 10% or risk factors worsen
LOW <5%YesNot routinely recommended — except BP persistently >160/100 mmHg (treat BP) or total cholesterol >7.5 mmol/L (treat lipids; consider FH)Every 5 years; sooner if close to 5% or risk factors change

First Nations people: reassess annually, ideally as part of the annual health assessment (MBS 715), and at least every 2 years.2

2.5 Reclassification factors ★★★☆

The calculator cannot include everything. Where the calculated risk is close to a category threshold, these factors can move a person up (or down) a category:1,2

Table 4a. Reclassification factors
FactorDetailDirection
First Nations peopleAfter considering clinical, psychological and socioeconomic circumstances and local CVD prevalenceConsider ↑
EthnicityMāori, Pacific Islander, South Asian (Indian, Pakistani, Bangladeshi, Sri Lankan, Nepali, Bhutanese, Maldivian)Consider ↑
EthnicityEast Asian (Chinese, Japanese, Korean, Taiwanese, Mongolian)Consider ↓
Family history of premature CVDCHD or stroke in a first-degree female relative <65 or male relative <55Consider ↑
CKD (without diabetes)eGFR 45–59 and/or uACR 2.5–25 (men) / 3.5–35 mg/mmol (women)Strongly consider ↑
Severe mental illnessCurrent or recent (within 5 years) condition needing specialist treatmentConsider ↑
Coronary artery calcium (CAC) scoreOnly when risk is low/intermediate and the treatment decision is uncertain. Not for population screening; not if already known CHD or high risk↑ or ↓

Not recommended for reclassification: routine ankle–brachial index, hs-CRP, or rheumatoid arthritis alone. Do ask about pregnancy history: hypertensive disorders of pregnancy and gestational diabetes increase later CVD risk.2

2.6 Assessment algorithm ★★★☆

Figure 3. CVD risk assessment and management in primary prevention, summarised from the 2023 Australian guideline.1

2.7 Old versus new: avoid the outdated answer ★★★★

Table 4b. 2012 (superseded) versus 2023 (current) absolute risk guidance
Feature2012 NVDPA (superseded)2023 guideline (current)
EquationFraminghamAus CVD Risk Calculator (PREDICT-based)
Ages45–74; First Nations from 3545–79; diabetes from 35; First Nations from 30
High risk>15%≥10%
Intermediate / moderate10–15%5 to <10%
Low<10%<5%
Automatic high riskDiabetes >60, diabetes + microalbuminuria, eGFR <45, FH, BP ≥180/110, TC >7.5, First Nations >74eGFR <45 or uACR >25/35, confirmed FH only
ReclassificationLimitedEthnicity, family history, CKD, severe mental illness, CAC

3. Hypertension ★★★★

3.1 Definitions and classification ★★★☆

Hypertension is diagnosed on repeated, properly measured readings, ideally confirmed out of the clinic. The current Australian classification for clinic BP is:3

Table 5. Classification of clinic BP in adults (Heart Foundation 2016)
CategorySystolic (mmHg)Diastolic (mmHg)
Optimal<120and<80
Normal120–129and/or80–84
High-normal130–139and/or85–89
Grade 1 (mild)140–159and/or90–99
Grade 2 (moderate)160–179and/or100–109
Grade 3 (severe)≥180and/or≥110
Isolated systolic hypertension≥140and<90

When systolic and diastolic fall into different categories, use the higher category.

3.2 Measuring BP properly ★★☆☆

Clinic technique

  • Seated, back supported, feet flat, legs uncrossed, after 5 minutes’ rest.
  • No caffeine, smoking or exercise in the previous 30 minutes.
  • Arm supported at heart level; correct cuff (bladder encircles ≥80% of the arm). A small cuff over-reads.
  • At least two readings 1–2 minutes apart; average them.
  • First visit: measure both arms; use the higher arm thereafter. A difference >15 mmHg suggests subclavian stenosis or coarctation.
  • Standing BP in older people and people with diabetes: orthostatic hypotension is a fall ≥20 systolic or ≥10 diastolic within 3 minutes.

Automated office BP (AOBP)

An automated device takes several readings while the patient sits alone in the room. It reduces the white-coat effect and gives readings closer to daytime ambulatory BP. The National Hypertension Taskforce recommends AOBP as the measurement standard for diagnosis and management in general practice.8

Note that the SPRINT trial (which supports lower targets) used unattended AOBP. Lower AOBP values are not directly comparable with attended manual readings.

3.3 Out-of-clinic measurement and diagnostic thresholds ★★★★

Clinic readings alone mislabel many people. If clinic BP is ≥140/90 (and not severely raised), confirm with ambulatory BP monitoring (ABPM) or home BP monitoring (HBPM) before labelling someone hypertensive.3

Table 6. Thresholds equivalent to clinic 140/90 mmHg
MethodHypertension if average isNotes
Clinic≥140/90Average of ≥2 readings on ≥2 occasions
ABPM — 24-hour≥130/80Gold standard. Shows nocturnal pattern (non-dipping is linked to higher risk, CKD and OSA). Hypertension if any threshold is exceeded
ABPM — daytime (awake)≥135/85
ABPM — night-time (asleep)≥120/70
HBPM≥135/85Validated upper-arm device. Duplicate readings morning and evening for 7 days; discard day 1; average the rest
Table 7. Clinic versus out-of-clinic patterns
 Out-of-clinic normalOut-of-clinic raised
Clinic normalNormotensionMasked hypertension — higher risk; suspect in smokers, people with diabetes, CKD or unexplained target-organ damage
Clinic raisedWhite-coat hypertension — no drugs, but monitor (annual out-of-clinic checks); higher risk of progressionSustained hypertension

Cuffless devices (smartwatches, rings) are not yet accurate enough to diagnose or titrate treatment.

3.4 Diagnostic pathway ★★★☆

Figure 4. Confirming a diagnosis of hypertension in general practice.

3.5 Initial assessment ★★★☆

Every person with confirmed hypertension needs three questions answered: What is their absolute risk? Is there target-organ damage? Could this be secondary hypertension?

Table 8. Baseline assessment
DomainWhat to doLooking for
HistoryDuration, prior readings, symptoms, family history, pregnancy history, sleep and snoring, alcohol, salt, drugs (prescribed, OTC, recreational)Secondary causes, OSA, drug-induced BP rise, other risk factors
ExaminationBMI and waist, both-arm BP, radio-femoral delay, abdominal bruit, thyroid, Cushingoid features, fundoscopy, heart and peripheral pulsesCoarctation, renovascular disease, endocrine causes, retinopathy, LVH, PAD
UrineDipstick (blood, protein) and urine albumin:creatinine ratio (uACR)Kidney damage; glomerular disease
BloodUEC and eGFR, fasting lipids, fasting glucose or HbA1c; consider TSH and calciumCKD, hypokalaemia (aldosteronism, diuretics), diabetes, lipids for risk calculation
ECG12-leadLVH, AF, previous infarction
SelectedEchocardiogram (LVH, valve disease); renal ultrasound; sleep studyGuided by findings

Secondary hypertension

Suspect a secondary cause when: onset before 30–40 or after 60; abrupt onset or sudden worsening; grade 3 or resistant hypertension; hypokalaemia; disproportionate target-organ damage; paroxysmal symptoms; or a rise in creatinine >30% after starting an ACE inhibitor or ARB.

Table 9. Secondary causes of hypertension
CauseCluesFirst test
Primary aldosteronismCommonest endocrine cause. Often normal potassium. Resistant HTN, hypokalaemia, adrenal incidentaloma, AF, OSA, family history of early strokeAldosterone:renin ratio (ARR), morning, after correcting K+. Many drugs interfere (see note below)
Renal parenchymal diseaseAbnormal eGFR, haematuria, proteinuria, history of diabetes, family history of polycystic kidneysUEC/eGFR, uACR, urine microscopy, renal ultrasound
Renovascular diseaseYoung woman (fibromuscular dysplasia); older person with atherosclerosis; abdominal bruit; flash pulmonary oedema; creatinine rise >30% on ACEi/ARBRenal artery duplex ultrasound or CT/MR angiography
Obstructive sleep apnoeaSnoring, witnessed apnoeas, daytime sleepiness, obesity, non-dipping on ABPMSTOP-Bang or Epworth score; sleep study
Drugs and substancesNSAIDs, combined oral contraceptive, corticosteroids, decongestants, SNRIs (venlafaxine), calcineurin inhibitors, stimulants, liquorice, excess alcohol, amphetamines, cocaineHistory; stop or substitute and recheck
Phaeochromocytoma / paragangliomaParoxysmal headache, sweating, palpitations, pallor; labile BPPlasma free metanephrines
Cushing syndromeCentral obesity, proximal myopathy, striae, easy bruising, diabetes1 mg overnight dexamethasone suppression test, 24-hour urinary free cortisol or late-night salivary cortisol
Thyroid / parathyroidHyper- or hypothyroid features; hypercalcaemiaTSH; calcium
Coarctation of the aortaYoung person; radio-femoral delay; arm BP higher than leg BP; murmurEchocardiogram; CT or MR angiography
Exam pearl — primary aldosteronism

Primary aldosteronism is under-diagnosed. The Endocrine Society’s 2025 guideline recommends screening all people with hypertension using the aldosterone:renin ratio.11 Many antihypertensives affect the result: diuretics, ACE inhibitors, ARBs and dihydropyridine CCBs can raise renin (false negative); beta-blockers lower renin (false positive). Spironolactone and eplerenone strongly interfere. Know the interferences, correct potassium first, and discuss with the testing laboratory or an endocrinologist rather than stopping drugs in someone with severe hypertension.

3.6 Who to treat with medicines ★★★★

Drug decisions combine the BP level with absolute risk:1,3

Table 10. Starting BP-lowering medicines
SituationAction
Established CVD, or high absolute risk (≥10% or clinically high)Start medicines plus lifestyle changes
BP persistently ≥160/100 at any level of riskStart medicines plus lifestyle changes
Target-organ damage, diabetes with albuminuria, CKDStart medicines (ACE inhibitor or ARB if albuminuria)
Intermediate risk (5 to <10%) with BP ≥140/90Shared decision; consider medicines, especially if lifestyle has not worked after 3–6 months
Low risk (<5%), grade 1Lifestyle; monitor; drugs only if BP stays above 160/100 or risk rises

3.7 Lifestyle measures ★★☆☆

Lifestyle measures are the foundation for everyone, whether or not they take medicines.

Table 11. Lifestyle measures and approximate effect on systolic BP
MeasureRecommendationApprox. SBP fall
Weight lossAim for healthy weight; waist <94 cm (men), <80 cm (women)About 1 mmHg per kg lost
Eating patternDASH or Mediterranean-style: vegetables, fruit, wholegrains, legumes, nuts, fish; low saturated fat8–14 mmHg
Salt<5 g salt (≈2000 mg sodium) per day. Potassium-enriched salt substitute (≈75% NaCl / 25% KCl) instead of table salt, unless at risk of hyperkalaemia (CKD, potassium-sparing diuretics, potassium supplements)82–8 mmHg
Physical activity150–300 min moderate (or 75–150 min vigorous) a week, plus muscle strengthening 2 days a week4–9 mmHg
AlcoholNo more than 10 standard drinks a week and no more than 4 on any day (NHMRC 2020); less is better2–4 mmHg
SmokingStop — does not lower BP much but greatly reduces CVD risk. Offer counselling, Quitline and pharmacotherapy—

Effect sizes are approximate, drawn from trial data commonly used in teaching; individual responses vary.

3.8 Choosing and stepping up medicines ★★★★

Four classes are first-line for uncomplicated hypertension: ACE inhibitors, angiotensin receptor blockers (ARBs), dihydropyridine calcium channel blockers and thiazide or thiazide-like diuretics.3,5 Beta-blockers are not first-line for uncomplicated hypertension; use them when there is another indication (angina, post-MI, heart failure with reduced EF, AF rate control).

What’s new — PBS, 1 April 2026

Dual-therapy antihypertensive fixed-dose combinations (single-pill combinations) can now be prescribed on the PBS as initial (first-line) treatment. 30-day packs became unrestricted; 60-day packs are restricted to people whose condition is stable.7 This aligns Australian practice with international guidelines (ESC 2024, AHA/ACC 2025), which favour starting most patients on a low-dose two-drug single pill. Monotherapy remains reasonable for frail or very old people and those with grade 1 hypertension at low risk.

Figure 5. Stepped drug treatment. A = ACE inhibitor or ARB; C = dihydropyridine calcium channel blocker; D = thiazide-like diuretic. Review every 4–6 weeks while titrating.3,5
Table 12. First-line drug classes
Class (examples)Preferred whenAvoid / cautionKey adverse effects and monitoring
ACE inhibitor
perindopril, ramipril
Diabetes, CKD with albuminuria, HFrEF, post-MIPregnancy (teratogenic) and women planning pregnancy; bilateral renal artery stenosis; history of angioedema; hyperkalaemiaDry cough (about 1 in 10), angioedema, hyperkalaemia, rise in creatinine. Check UEC 1–2 weeks after starting or dose increase; a creatinine rise up to 30% is acceptable
ARB
candesartan, irbesartan, telmisartan
As for ACE inhibitor; ACE-inhibitor coughAs for ACE inhibitor. Never combine ACEi + ARBHyperkalaemia, rise in creatinine; cough is uncommon
Dihydropyridine CCB
amlodipine, felodipine, lercanidipine
Older people, isolated systolic hypertension, anginaDo not confuse with non-dihydropyridine CCBs (verapamil, diltiazem), which are avoided in HFrEF. Amlodipine and felodipine are safe in HFrEF but do not improve outcomesDose-related ankle oedema (not helped by diuretics; less with an ACEi/ARB), flushing, headache, gum hypertrophy
Thiazide-like diuretic
indapamide, chlortalidone, hydrochlorothiazide (combinations)
Older people, isolated systolic hypertension, heart failureGout, significant hyponatraemia or hypokalaemiaHyponatraemia (especially older women), hypokalaemia, hyperuricaemia/gout, hyperglycaemia. Check UEC within weeks
⚠ Safety alerts
  • “Triple whammy”: ACE inhibitor or ARB + diuretic + NSAID can cause acute kidney injury, especially with dehydration (sick-day rules: withhold during vomiting or diarrhoea).
  • Hyperkalaemia: ACEi/ARB + spironolactone, potassium supplements, trimethoprim or potassium salt substitutes, especially with CKD.
  • Pregnancy: stop ACE inhibitors and ARBs before conception or as soon as pregnancy is confirmed. Use labetalol, nifedipine (modified release) or methyldopa.10
  • Do not combine a beta-blocker with verapamil or diltiazem (heart block, bradycardia).
  • Do not use sublingual nifedipine or rapid-acting agents to lower BP quickly in general practice.

3.9 Targets ★★★☆

Table 13. BP targets
GroupAustralian target (HF 2016)Notes and newer evidence
Most adults with hypertension<140/90For high-risk people, a systolic target <120 (measured by unattended AOBP) can be considered if tolerated (SPRINT). ESC 2024 suggests 120–129 systolic if tolerated; AHA/ACC 2025 suggests <130/80
Diabetes<140/90Systolic <120 may be considered where stroke prevention is prioritised. ACEi/ARB first-line if albuminuria
CKD<140/90Systolic <120 may be considered with careful monitoring. ACEi/ARB if albuminuria; monitor eGFR and K+
After stroke or TIA<140/90Stroke Foundation living guidelines support lower targets (generally <130/80) for most survivors9
Age ≥75 or frailIndividualiseTreatment still benefits people ≥80 (HYVET). Check standing BP; watch for falls, hyponatraemia and AKI; deprescribe where harms outweigh benefits

3.10 Follow-up and monitoring ★★☆☆

  • Review every 4–6 weeks while titrating; once at target, every 3–6 months.
  • Encourage home BP monitoring with a validated device for titration and adherence.
  • UEC 1–2 weeks after starting or increasing an ACE inhibitor, ARB, diuretic or spironolactone; then at least yearly with uACR, lipids and HbA1c/glucose.
  • Ask about adherence at every visit. Single-pill combinations improve adherence.
  • Consider stopping or reducing medicines after sustained major lifestyle change, with monitoring.

3.11 Hypertensive urgency and emergency ★★★★

Hypertensive emergency

Severely raised BP (usually ≥180/110, often much higher) with acute target-organ damage: hypertensive encephalopathy, stroke, acute coronary syndrome, acute pulmonary oedema, aortic dissection, AKI, malignant hypertension (retinal haemorrhages, exudates, papilloedema), or pre-eclampsia/eclampsia.

Action: ambulance to ED for controlled IV treatment.

Severe hypertension without organ damage

Severely raised BP but no acute organ damage (sometimes called “urgency”).

Action: repeat after rest; look for triggers (pain, anxiety, missed doses, NSAIDs, drugs); start or adjust oral therapy; lower gradually over days to weeks; review within a few days. Rapid lowering risks stroke and myocardial ischaemia.

3.12 Special groups ★★★☆

Table 14. Special populations
GroupKey points
First Nations peopleCVD risk assessment from 30 (risk factors from 18); annual health check (MBS 715); consider reclassifying upward; culturally safe, shared decision-making; high rates of CKD — always check uACR12
Women of reproductive ageAvoid ACEi/ARB unless reliable contraception and counselled; plan switch before conception. Ask about previous pre-eclampsia, gestational hypertension and gestational diabetes (higher lifelong CVD risk)
PregnancyHypertension ≥140/90; labetalol, nifedipine or methyldopa; aspirin from <16 weeks for women at high risk of pre-eclampsia. Covered in the Women’s Health chapter10
Older peopleIsolated systolic hypertension is common; CCB or thiazide-like diuretic work well; check postural BP; start low and go slow
Young adults (<30–40)Look for secondary causes (renal disease, aldosteronism, coarctation, fibromuscular dysplasia, drugs)
ChildrenUse age-, sex- and height-based centiles; covered in the Child and Youth Health chapter

4. Prevention, screening and Medicare items ★★★☆

Table 15. Screening and assessment in general practice
ActivityWho and how often
Blood pressureAll adults from 18, at least every 2 years (more often if high-normal or other risk factors) — RACGP Red Book6
Absolute CVD risk45–79; diabetes 35–79; First Nations 30–79. Low risk: every 5 years; intermediate (untreated): every 2 years; First Nations: yearly, at least every 2 years
Heart Health Check (MBS 699; 177 for practitioners other than GPs)At least 20 minutes; once in 12 months; includes Aus CVD Risk Calculator assessment, management plan and recall. Items currently extended to June 202813
Aboriginal and Torres Strait Islander health assessment (MBS 715)Annual; includes BP and CVD risk assessment
Where candidates lose marks

From the RACGP KFP 2025.1 public exam report15

  • Hypertension in a young adult: some candidates gave follow-up investigations when initial ones were asked for, and some assumed history that was not in the stem (such as sleep apnoea).
  • Raised aldosterone:renin ratio: the expected answer was referral to a non-GP specialist. Spironolactone was the only appropriate medicine; other drug choices scored no marks.
  • CVD risk assessment: candidates who knew the updated calculator did well. Common errors were ordering thyroid function tests that were not indicated and missing that a low-risk patient did not need a statin.
  • Answer technique: giving more answers than requested costs marks, and vague answers (e.g. “reduce alcohol” instead of a specific limit) score poorly.

Other common traps

  • Answering from the 2012 risk categories (>15% high risk).
  • Labelling hypertension from clinic readings alone without ABPM or HBPM confirmation.
  • Choosing a beta-blocker as first-line for uncomplicated hypertension.

5. Worked cases (KFP format)

How the KFP works now. Since the 2025.2 sitting the KFP has been 70 separate scenarios in four hours, each with one multiple-selection question. The question tells you how many options to select, and there is no penalty for a wrong choice. However, each bubble you shade beyond the number requested costs 0.35% of your overall mark.17 Tick your answers below, then open the answer to see your score.
KFP case 1

Stefan Kowalski, aged 52 years, a bus driver, returns to discuss his 24-hour ambulatory blood pressure monitoring. You arranged it after clinic readings of 152/96 mmHg and 150/94 mmHg at two visits. The daytime average was 149/95 mmHg* and the 24-hour average was 143/90 mmHg*.

He feels well and has no chest pain, breathlessness or headaches. He has had no episodes of palpitations or sweating. His wife says he does not snore and he does not feel sleepy during the day. He has never smoked, drinks six standard drinks a week, and takes no prescribed or over-the-counter medicines or supplements. He has no known cardiovascular disease.

Examination findings:

  • Appears well
  • Heart rate 72/min regular
  • Blood pressure 150/94 mmHg* in both arms
  • BMI 26 kg/m2
  • Neck examination – no goitre
  • Cardiovascular examination – normal heart sounds with no murmurs; radial and femoral pulses equal and synchronous; all foot pulses present
  • Abdominal examination – no masses or bruits
  • Fundoscopy – normal

Physical examination is otherwise unremarkable, with no Cushingoid features. A urine dipstick in the clinic today shows no blood or protein. An HbA1c at a work medical three months ago was 5.3%.

What are the MOST appropriate investigations to request today? Select four (4) from the following list.

Maximum Score: 4

Show answer

You ticked options, and of the 4 keyed answers.

Answers: A, H, M, N.

Feedback: Stefan has grade 1 hypertension confirmed on ambulatory monitoring, with no symptoms, no target-organ damage on examination and no clues to a secondary cause. The baseline work-up for every person with newly confirmed hypertension answers three questions: what is his absolute risk, is there target-organ damage, and could this be secondary hypertension? Urea, electrolytes and creatinine with eGFR detect CKD and the hypokalaemia that suggests aldosteronism. The urine albumin:creatinine ratio detects early kidney damage, and both results can place him in a higher risk category. A lipid profile is needed to run the Aus CVD Risk Calculator, and a 12-lead ECG looks for left ventricular hypertrophy, atrial fibrillation or a previous infarct.

Some tests are already done. His dipstick is negative today and his HbA1c was normal three months ago, so repeating them adds nothing. Tests for specific secondary causes need a clinical clue, and the stem removes each one. He has no paroxysmal symptoms (metanephrines), no Cushingoid features (cortisol), no bruit and no age or history pointing to renovascular disease (renal duplex), and no snoring or daytime sleepiness (polysomnography). Thyroid function tests ordered without thyroid features were a common source of lost marks in the 2025.1 KFP report. An echocardiogram is a selected test guided by findings such as LVH on ECG or a murmur. hs-CRP and routine ankle–brachial index are not recommended for reclassifying risk, and a coronary artery calcium score is only considered after the calculator leaves a treatment decision uncertain.

Reference: Heart Foundation guideline for the diagnosis and management of hypertension in adults 2016; RACGP KFP 2025.1 public exam report.

Got this wrong? Re-read 3.5 Initial assessment →

KFP case 2

Rosa Esposito, aged 74 years, attends for review of her blood pressure. It has been well controlled for five years, most recently 128/76 mmHg six months ago. Three weeks ago a locum started her on meloxicam for right knee pain. The pain has improved. Her home readings this week, taken with a validated upper-arm device, have averaged 156/88 mmHg*.

She has no headache, chest pain, breathlessness, visual change or neurological symptoms, and no vomiting or diarrhoea. She is eating and drinking normally.

Past medical history:Medications:
Hypertension
Osteoarthritis – right knee
Meloxicam 15 mg daily
Perindopril–indapamide 4 mg/1.25 mg daily

Her blood pressure in the clinic is 158/86 mmHg* and her heart rate is 76/min regular. She is not dehydrated. Her right knee has bony enlargement and crepitus with no effusion or warmth.

BiochemistrySix months agoTodayNormal range
Sodium139137135–145 mmol/L
Potassium4.54.93.5–5.2 mmol/L
Creatinine8092*45–90 µmol/L
eGFR6454*>60 mL/min/1.73 m2

You discuss non-drug measures for her knee osteoarthritis, and she agrees to see a physiotherapist.

What is the MOST appropriate management? Select three (3) from the following list.

Maximum Score: 3

Show answer

You ticked options, and of the 3 keyed answers.

Answers: B, D, J.

Feedback: Rosa’s blood pressure was controlled for five years and rose after she started an NSAID. Her eGFR has also fallen. She is taking the “triple whammy” combination: an ACE inhibitor, a diuretic and an NSAID, which can cause acute kidney injury, especially in an older person who becomes dehydrated. The key decision is to remove the cause rather than add to her antihypertensives. Cease meloxicam, and repeat UEC in one week to confirm that her creatinine returns towards baseline; three months is too long to leave a falling eGFR unchecked. She also needs sick-day advice: withhold perindopril–indapamide during vomiting or diarrhoea and restart once she is eating and drinking normally.

Changing to celecoxib or halving the meloxicam dose keeps an NSAID in the combination. Withholding her antihypertensive now is wrong, because she is not dehydrated, her BP is raised and her creatinine has risen by much less than 30%. Adding amlodipine, increasing perindopril–indapamide or arranging ambulatory monitoring treats or investigates a BP rise that has an obvious reversible cause; recheck her BP after the NSAID has been stopped. A modest fall in eGFR with a clear precipitant does not need nephrology referral. Opioids are not recommended for knee osteoarthritis and add risks of falls and constipation at her age.

Reference: Therapeutic Guidelines: Cardiovascular (current version); Australian Medicines Handbook 2026.

Got this wrong? Re-read 3.8 Choosing and stepping up medicines →

KFP case 3

Leanne Morgan, aged 67 years, attends for a Heart Health Check. She has no known cardiovascular disease and does not have diabetes. She is a non-smoker and takes no regular medicines.

Her blood pressure is 144/84 mmHg* and 142/82 mmHg. Her total cholesterol is 5.8 mmol/L* and HDL cholesterol is 1.3 mmol/L. Her eGFR is 82 mL/min/1.73 m2 and her urine albumin:creatinine ratio is 1.1 mg/mmol. Her estimated 5-year risk using the Aus CVD Risk Calculator is 8%.

Leanne says she would rather avoid medicines unless her risk is high. You have not yet taken a full family and social history.

What additional aspects of history would MOST support reclassifying her cardiovascular risk as high? Select three (3) from the following list.

Maximum Score: 3

Show answer

You ticked options, and of the 3 keyed answers.

Answers: A, C, F.

Feedback: Leanne’s calculated 5-year risk of 8% is intermediate but close to the 10% high-risk threshold, and whether she takes medicines depends on which side of that line she falls. The 2023 guideline lists factors the calculator does not include that can move a person up a category when they are near a threshold. A brother with a myocardial infarction at 49 is premature CVD in a male first-degree relative (under 55). Bipolar disorder needing specialist care within the past five years is a severe mental illness. Being an Aboriginal woman supports upward reclassification once her clinical, psychological and socioeconomic circumstances and local CVD prevalence are considered.

The siblings fail on a single parameter. Her father’s infarct at 68 is not premature, and a single episode of postnatal depression 30 years ago is neither severe nor recent. East Asian ethnicity, such as parents born in Japan, points towards downward reclassification. A deep vein thrombosis is venous, not atherosclerotic, disease. The guideline does not recommend using hs-CRP or rheumatoid arthritis alone for reclassification. Smoking status is already a calculator input, and she stopped 25 years ago. Drinking within the national limit and menopause at a typical age do not change her category. If the decision is still uncertain after taking the history, a coronary artery calcium score can help.

Reference: Australian guideline for assessing and managing cardiovascular disease risk 2023.

Got this wrong? Re-read 2.5 Reclassification factors →

6. Self-check questions

These questions are written at or above AKT difficulty. Every option is plausible and the options are deliberately similar. Commit to an answer before revealing the explanation.

⏱ Exam-pace challenge. The AKT gives you 4 hours for 150 questions — about 1.6 minutes each.17 Time yourself: Questions 1–5 in 8 minutes, then 6–10 in 8 minutes. Rate your confidence honestly before you reveal each answer.
Question 1

Daniel Okafor, aged 49 years, had clinic blood pressure readings of 146/92 mmHg and 144/90 mmHg at two visits a fortnight apart. He has no symptoms and no known cardiovascular disease.

His 24-hour ambulatory blood pressure monitoring shows a 24-hour average of 129/79 mmHg, a daytime average of 133/84 mmHg and a night-time average of 121/68 mmHg*.

What is the MOST appropriate interpretation of his ambulatory blood pressure?

How sure are you?
Show answer

⚠ You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.

Right, but you guessed. Treat this as not yet learnt.

Sure and right — this one is secure.

Answer: C. Hypertension confirmed by the night-time average

Feedback: This question requires candidates to apply each ambulatory threshold separately. Hypertension is present if any ABPM average reaches its threshold: 24-hour ≥130/80, daytime ≥135/85 or night-time ≥120/70 mmHg. Only the night-time systolic (121) reaches its threshold.

  • Hypertension confirmed by the 24-hour average: 129/79 is just below 130/80.
  • Hypertension confirmed by the daytime average: 133/84 is below 135/85.
  • Masked hypertension needing home monitoring: masked hypertension means normal clinic BP; his clinic readings were raised.
  • Normal ambulatory readings, white-coat effect: the night-time average is abnormal, so this is not white-coat hypertension.

Reference: National Heart Foundation of Australia. Guideline for the diagnosis and management of hypertension in adults, 2016.

Got this wrong? Re-read 3.3 Out-of-clinic measurement and diagnostic thresholds →

Question 2

Kirra Thompson, aged 41 years, is an Aboriginal woman attending her local Aboriginal Community Controlled Health Service for her annual health assessment. She does not smoke and has no known cardiovascular disease or diabetes.

Her blood pressure is 128/80 mmHg and her total cholesterol is 4.9 mmol/L. Her estimated 5-year risk using the Aus CVD Risk Calculator is 4%. After discussion she does not wish to take medicines.

What is the MOST appropriate interval for reassessing her cardiovascular risk?

How sure are you?
Show answer

⚠ You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.

Right, but you guessed. Treat this as not yet learnt.

Sure and right — this one is secure.

Answer: A. Reassess her CVD risk in 12 months

Feedback: This question requires candidates to apply the population-specific reassessment interval in the 2023 guideline. For First Nations people, CVD risk should be reassessed annually (for example at the annual health assessment), and at least every 2 years. Her low calculated risk does not change this.

  • Reassess her CVD risk in 2 years: this is the minimum acceptable interval for First Nations people and the interval for intermediate risk; annual reassessment is preferred and fits her annual health check.
  • Reassess her CVD risk in 3 years: not a guideline interval.
  • Reassess her CVD risk in 5 years: the interval for low risk in the general population, the main trap.
  • Reassess her CVD risk in 6 months: more frequent than recommended.

Reference: Commonwealth of Australia. Australian guideline for assessing and managing cardiovascular disease risk, 2023.

Got this wrong? Re-read 2.4 Risk categories and what to do →

Question 3

Josephine Clarke, aged 58 years, attends for cardiovascular risk assessment. She does not have diabetes or known cardiovascular disease.

Her eGFR has been 52 mL/min/1.73m²* and 54 mL/min/1.73m²* three months apart. Her urine albumin:creatinine ratio has been 30 mg/mmol* and 28 mg/mmol* on the same occasions. Her estimated 5-year risk using the Aus CVD Risk Calculator is 8%.

What is the MOST appropriate classification of her cardiovascular risk?

How sure are you?
Show answer

⚠ You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.

Right, but you guessed. Treat this as not yet learnt.

Sure and right — this one is secure.

Answer: A. High risk, after reclassification for kidney disease

Feedback: This question requires candidates to separate the clinically determined high-risk CKD thresholds from the reclassification range. For a woman, clinically determined high risk needs sustained eGFR <45 or persistent uACR >35 mg/mmol. Her values (eGFR 45–59, uACR 3.5–35) fall in the range where the guideline advises strongly considering moving up a category, and her calculated 8% is close to the 10% threshold.

  • High risk, clinically determined by her albuminuria: the female threshold is >35 mg/mmol; >25 applies to men.
  • High risk, clinically determined by her reduced eGFR: clinically determined high risk needs sustained eGFR <45.
  • Intermediate risk, as calculated, reassess in 2 years: ignores a reclassification factor the guideline says to strongly consider.
  • Intermediate risk, reassess after a repeat uACR test: albuminuria is already shown to be persistent.

Reference: Nelson MR, et al. 2023 Australian guideline for assessing and managing cardiovascular disease risk. Med J Aust 2024.

Got this wrong? Re-read 2.5 Reclassification factors →

Question 4

Grace Walker, aged 71 years, started candesartan 8 mg daily 10 days ago for hypertension. She feels well and has no postural symptoms. Her blood pressure today is 142/80 mmHg.

BiochemistryBeforeTodayNormal range
Sodium139138135–145 mmol/L
Potassium4.65.03.5–5.2 mmol/L
Creatinine96118*45–90 µmol/L

What is the MOST appropriate next step?

How sure are you?
Show answer

⚠ You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.

Right, but you guessed. Treat this as not yet learnt.

Sure and right — this one is secure.

Answer: D. Continue candesartan and repeat UEC in two weeks

Feedback: This question requires candidates to recognise an expected haemodynamic rise in creatinine after starting an ARB. Her creatinine has risen by 23% and potassium remains normal. A rise of up to 30% is acceptable; continue treatment and recheck. A rise above 30%, or hyperkalaemia, would prompt dose reduction or cessation and consideration of renovascular disease.

  • Cease candesartan and arrange renal artery duplex: appropriate for a rise above 30%, not 23%.
  • Cease candesartan and start amlodipine instead: abandons an effective drug for an acceptable change.
  • Change candesartan to perindopril and repeat UEC: an ACE inhibitor has the same renal effect.
  • Halve candesartan dose and repeat UEC in one week: dose reduction is not needed below a 30% rise.

Reference: Therapeutic Guidelines. Cardiovascular: hypertension (current version); Australian Medicines Handbook 2026.

Got this wrong? Re-read 3.8 Choosing and stepping up medicines →

Question 5

Anika Sharma, aged 31 years, wants to start trying for a pregnancy in the next three months. Her hypertension is well controlled on perindopril 5 mg daily.

She has moderate asthma treated with budesonide–formoterol, and depression that has been stable for two years on sertraline 100 mg daily.

What is the MOST appropriate change to her antihypertensive treatment?

How sure are you?
Show answer

⚠ You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.

Right, but you guessed. Treat this as not yet learnt.

Sure and right — this one is secure.

Answer: E. Change to nifedipine MR 30 mg once daily

Feedback: This question requires candidates to choose a pregnancy-compatible antihypertensive under two patient-specific constraints. ACE inhibitors should be stopped before conception. Of the first-line pregnancy agents, labetalol is a beta-blocker and is avoided in asthma, and methyldopa can worsen depression. Modified-release nifedipine suits her.

  • Change to candesartan 8 mg once daily: ARBs carry the same fetal risks as ACE inhibitors.
  • Change to hydralazine 25 mg twice daily: not a first-line oral maintenance agent; reserved for later lines or acute use.
  • Change to labetalol 100 mg twice daily: first-line in pregnancy, but contraindicated by her asthma.
  • Change to methyldopa 250 mg twice daily: first-line in pregnancy, but can cause or worsen depression.

Reference: SOMANZ. Hypertension in pregnancy guideline, 2023.

Got this wrong? Re-read 3.8 Choosing and stepping up medicines →

Question 6

Margaret Ellis, aged 64 years, has clinic blood pressure readings of 156/90, 158/92 and 154/88 mmHg over three visits. She takes full doses of perindopril, amlodipine and indapamide. Pharmacy dispensing records confirm she collects every script on time. She says her readings are always normal on the pharmacy machine.

Her electrolytes, eGFR and aldosterone:renin ratio are normal. She has never had out-of-clinic blood pressure measurement.

What is the MOST appropriate next step?

How sure are you?
Show answer

⚠ You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.

Right, but you guessed. Treat this as not yet learnt.

Sure and right — this one is secure.

Answer: D. Arrange 24-hour ambulatory BP monitoring

Feedback: This question requires candidates to exclude pseudo-resistance before diagnosing resistant hypertension. Adherence is confirmed and secondary causes have been screened, but out-of-clinic BP has never been measured and she reports normal readings elsewhere, suggesting a white-coat effect. ABPM confirms or refutes true resistance before a fourth drug is added.

  • Add bisoprolol 2.5 mg once daily: a fourth-line option, and premature.
  • Add moxonidine 200 mcg once daily: a later-line option, and premature.
  • Add spironolactone 25 mg once daily: the preferred fourth drug once resistance is confirmed, not before.
  • Refer to a hypertension specialist now: reasonable if resistance is confirmed; the basic step comes first.

Reference: National Heart Foundation of Australia. Guideline for the diagnosis and management of hypertension in adults, 2016.

Got this wrong? Re-read 3.8 Choosing and stepping up medicines →

Question 7

Liam O’Brien, aged 52 years, has hypertension confirmed on ambulatory monitoring, with a daytime average of 162/101 mmHg. His estimated 5-year CVD risk is 7%. After discussion he has decided against lipid-lowering therapy.

He has gout and takes allopurinol 300 mg daily. Several years ago he stopped ramipril because of a persistent dry cough. His eGFR and urine albumin:creatinine ratio are normal.

What is the MOST appropriate initial pharmacological management?

How sure are you?
Show answer

⚠ You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.

Right, but you guessed. Treat this as not yet learnt.

Sure and right — this one is secure.

Answer: D. Telmisartan/amlodipine 40 mg/5 mg daily

Feedback: This question requires candidates to choose an initial single-pill combination that fits three constraints. His BP warrants treatment at any level of risk (>160/100), and is more than 20/10 above target, so a dual combination is appropriate (PBS-listed as initial therapy from April 2026). ACE-inhibitor cough is a class effect, so use an ARB; gout makes a thiazide-like diuretic less suitable.

  • Amlodipine/atorvastatin 5 mg/10 mg daily: only one BP-lowering drug, and he has declined lipid-lowering therapy.
  • Perindopril/amlodipine 5 mg/5 mg daily: contains an ACE inhibitor despite his ACE-inhibitor cough.
  • Perindopril/indapamide 5 mg/1.25 mg daily: ACE inhibitor plus a diuretic that can worsen gout.
  • Trandolapril/verapamil 2 mg/180 mg daily: contains an ACE inhibitor, and a non-dihydropyridine CCB is not a preferred first-line partner.

Reference: PBS. Restriction changes for antihypertensive dual therapy fixed dose combinations, 1 April 2026; Therapeutic Guidelines. Cardiovascular.

Got this wrong? Re-read 3.8 Choosing and stepping up medicines →

Question 8

Tom Hughes, aged 66 years, attends for a routine review. His blood pressure is 192/114 mmHg* and 188/112 mmHg* after 10 minutes’ rest. He ran out of his perindopril and amlodipine one week ago.

He has no headache, chest pain, dyspnoea, visual change or neurological symptoms. Fundoscopy shows no haemorrhages, exudates or papilloedema. His ECG is unchanged from last year, and a point-of-care creatinine is at his usual baseline.

What is the MOST appropriate management?

How sure are you?
Show answer

⚠ You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.

Right, but you guessed. Treat this as not yet learnt.

Sure and right — this one is secure.

Answer: D. Restart his usual medicines, review in two days

Feedback: This question requires candidates to distinguish severe hypertension without acute organ damage from a hypertensive emergency. There are no symptoms or signs of acute target-organ damage, and there is an obvious cause (stopping his medicines). BP should be lowered gradually with oral therapy and early review; rapid lowering risks cerebral and myocardial ischaemia.

  • Arrange ABPM before restarting any medicine: delays treatment of grade 3 hypertension in a known hypertensive patient.
  • Give captopril 25 mg now, recheck in one hour: rapid lowering is unnecessary and potentially harmful.
  • Give nifedipine 10 mg immediate release now: causes abrupt, unpredictable falls in BP and should not be used.
  • Transfer to the emergency department by ambulance: reserved for hypertensive emergency with acute organ damage.

Reference: Therapeutic Guidelines. Cardiovascular: hypertensive emergencies and severe hypertension (current version).

Got this wrong? Re-read 3.11 Hypertensive urgency and emergency →

Question 9

Helen Nguyen, aged 57 years, has type 2 diabetes. Her clinic blood pressure has been 128/78 and 126/76 mmHg. An ECG shows voltage criteria for left ventricular hypertrophy, and her urine albumin:creatinine ratio is 6.2 mg/mmol* on two occasions.

Her home blood pressure readings, taken twice morning and evening for seven days with a validated device, average 128/79 mmHg.

What is the MOST appropriate investigation to determine whether she has hypertension?

How sure are you?
Show answer

⚠ You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.

Right, but you guessed. Treat this as not yet learnt.

Sure and right — this one is secure.

Answer: A. 24-hour ambulatory blood pressure monitoring

Feedback: This question requires candidates to suspect masked or nocturnal hypertension when target-organ damage is out of proportion to normal clinic and home readings. Home monitoring measures only daytime BP; ABPM is the only test that captures night-time BP, which is often raised in diabetes and CKD.

  • Plasma aldosterone to renin ratio this week: screens for a cause, but hypertension has not yet been shown.
  • Renal artery duplex ultrasound within a month: nothing points to renovascular disease.
  • Repeat home blood pressure readings for 7 days: repeats a normal daytime test and still misses nocturnal BP.
  • Transthoracic echocardiogram within a month: characterises LVH but does not diagnose hypertension.

Reference: National Heart Foundation of Australia. Guideline for the diagnosis and management of hypertension in adults, 2016.

Got this wrong? Re-read 3.3 Out-of-clinic measurement and diagnostic thresholds →

Question 10

Ella Brooks, aged 27 years, has newly confirmed hypertension, with an ambulatory daytime average of 168/104 mmHg. She takes no medicines or supplements and does not snore. She has had no episodes of palpitations, sweating or headache, and no fevers, weight loss or joint pains.

On examination, blood pressure is the same in both arms and radial and femoral pulses are equal and synchronous. There is a bruit in the epigastrium. BMI is 22 kg/m².

Electrolytes, eGFR, urinalysis and the aldosterone:renin ratio are normal. Renal ultrasound shows normal-sized kidneys without cysts.

What is the MOST appropriate provisional diagnosis?

How sure are you?
Show answer

⚠ You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.

Right, but you guessed. Treat this as not yet learnt.

Sure and right — this one is secure.

Answer: C. Fibromuscular dysplasia

Feedback: This question requires candidates to recognise renovascular hypertension in a young woman. Severe hypertension at 27, an epigastric (renal artery) bruit and normal screening for other causes point to fibromuscular dysplasia. The next step is renal artery imaging (duplex ultrasound or CT angiography).

  • Coarctation of the aorta: excluded by equal, synchronous radial and femoral pulses.
  • Cushing syndrome: no clinical features are described.
  • Obstructive sleep apnoea: normal BMI and no snoring.
  • Phaeochromocytoma: no paroxysmal symptoms.
  • Polycystic kidney disease: excluded by the renal ultrasound.
  • Primary aldosteronism: the aldosterone:renin ratio is normal.
  • Takayasu arteritis: no systemic symptoms and no pulse or arm BP asymmetry.

Reference: Therapeutic Guidelines. Cardiovascular: secondary hypertension (current version).

Got this wrong? Re-read 3.5 Initial assessment →

Self-check score: / 10

Sure but wrong:

Any “sure but wrong” answer is your highest exam risk. Re-read those sections first, then use the flashcards below. Your selections are not saved; the score resets when you leave the page.

Exam-readiness check

Tick each one you can do without notes. Anything left unticked is your revision list.

Ready on of 9.

7. Key takeaways

Remember for the exam
  • Ages: calculator 45–79; diabetes from 35; First Nations from 30 (risk factors from 18).
  • Categories (5-year risk): high ≥10%, intermediate 5 to <10%, low <5%.
  • High without calculator: established CVD (secondary prevention), eGFR <45 or uACR >25 (M)/>35 (F), confirmed FH. Diabetes alone is no longer automatic high risk.
  • Reassess: low every 5 years, intermediate (untreated) every 2 years, First Nations yearly.
  • Treat regardless of risk if BP persistently >160/100 or TC >7.5.
  • Confirm hypertension with ABPM (24 h ≥130/80, day ≥135/85, night ≥120/70) or HBPM (≥135/85).
  • First-line: ACEi/ARB, dihydropyridine CCB, thiazide-like diuretic. Dual single-pill combinations are PBS-listed as initial therapy from April 2026.
  • Resistant hypertension: confirm adherence, exclude secondary causes, then add spironolactone.
  • Avoid: ACEi/ARB in pregnancy; ACEi + ARB together; the triple whammy.
  • Watch: the 2027 Australian hypertension guideline will update thresholds and targets.

Your revision plan

Spaced revision for this lesson
WhenWhat to do
TodayFinish the lesson, both question sets and the readiness checklist. Note every “sure but wrong” answer.
Day 3Do this lesson’s 10 flashcards again (end of this lesson). Re-read every section you marked “Not yet”.
Day 7Redo the self-check questions without looking at the lesson. Aim for 8/10 with no “sure but wrong”.
Day 21Do the cardiovascular chapter flashcard deck, then one timed block of mixed cardiovascular questions at exam pace.
Week before the examRe-read the key takeaways and the old-notes box. Do the chapter flashcard deck once more.

Your next step

Use your scores from the cold-start check and the self-check questions to choose your next step.

Self-check under 6/10, or any “sure but wrong”: your knowledge has gaps you may not have noticed. Start the flashcards for this lesson today and re-read the sections you missed.This lesson’s 10 flashcards
6–8/10: the knowledge is there but not yet secure. Do the flashcards daily for a week, then redo the self-check.Start the flashcards
9–10/10 with no confident errors: move on to the next lesson and keep this topic fresh with the full cardiovascular deck once a week.Cardiovascular chapter deck

Flashcards: 10 high-yield recall cards

Finish the lesson by testing your recall. Say the answer out loud before you tap the card to flip it, then mark “I knew this” only if you were fully right without looking. Repeat the cards on day 3 and day 21, and use the cardiovascular chapter deck for later reviews.

Card 1 of 10 · Section 2.1

← Previous

Card 2 of 10 · Section 2.4

Card 3 of 10 · Section 2.2

Card 4 of 10 · Section 2.4

Card 5 of 10 · Section 2.4

Card 6 of 10 · Section 3.3

Card 7 of 10 · Section 3.5

Card 8 of 10 · Section 3.8

Card 9 of 10 · Section 3.8

Card 10 of 10 · Section 3.8

Knew it: / 10 known

8. References and recommended reading

References

  1. Commonwealth of Australia, Department of Health and Aged Care. Australian guideline for assessing and managing cardiovascular disease risk. Canberra: Commonwealth of Australia; 2023. Available at cvdcheck.org.au (accessed 9 Nov 2026).
  2. Nelson MR, et al. 2023 Australian guideline for assessing and managing cardiovascular disease risk. Med J Aust 2024;220(9):482–90. MJA
  3. National Heart Foundation of Australia. Guideline for the diagnosis and management of hypertension in adults – 2016. Melbourne: NHFA; 2016. Summary: Gabb GM, Mangoni AA, Anderson CS, et al. Med J Aust 2016;205(2):85–9.
  4. Heart Foundation, Stroke Foundation, Hypertension Australia. Draft 2027 Australian guideline for elevated blood pressure and hypertension in adults – public consultation (24 Sep–12 Oct 2026). Stroke Foundation (accessed 9 Nov 2026).
  5. Therapeutic Guidelines. Cardiovascular (current version, eTG complete). Melbourne: Therapeutic Guidelines Ltd. And: Australian Medicines Handbook 2026. Adelaide: AMH Pty Ltd; 2026.
  6. The Royal Australian College of General Practitioners. Guidelines for preventive activities in general practice (the Red Book). 10th edn. Melbourne: RACGP; 2024.
  7. Pharmaceutical Benefits Scheme. PBS restriction changes for antihypertensive dual therapy fixed dose combinations, 1 April 2026. pbs.gov.au (accessed 9 Nov 2026).
  8. National Hypertension Taskforce of Australia. Roadmap, AOBP position statement and potassium-enriched salt position statement (2026). hypertensiontaskforce.au (accessed 9 Nov 2026).
  9. Stroke Foundation. Living clinical guidelines for stroke management. Melbourne: Stroke Foundation; current version. informme.org.au
  10. Society of Obstetric Medicine of Australia and New Zealand (SOMANZ). Hypertension in pregnancy guideline. 2023.
  11. Adler GK, et al. Primary aldosteronism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2025.
  12. NACCHO and RACGP. National guide to preventive healthcare for Aboriginal and Torres Strait Islander people. 4th edn. Melbourne: RACGP; 2024.
  13. Services Australia / MBS Online. Heart Health Check items 699 and 177. mbsonline.gov.au; Heart Foundation Heart Health Check toolkit (accessed 9 Nov 2026).
  14. SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2103–16. Beckett NS, et al (HYVET). N Engl J Med 2008;358:1887–98. Williams B, et al (PATHWAY-2). Lancet 2015;386:2059–68.
  15. The Royal Australian College of General Practitioners. KFP 2025.1 public exam report. Melbourne: RACGP; 2025. racgp.org.au (accessed 10 Nov 2026).
  16. The Royal Australian College of General Practitioners. AKT 2026.2 public exam report. Melbourne: RACGP; 2026. racgp.org.au (accessed 10 Nov 2026).
  17. The Royal Australian College of General Practitioners. AKT and KFP: general exam delivery information. racgp.org.au (accessed 10 Nov 2026).

Recommended reading for RACGP fellowship candidates

  • Aus CVD Risk Calculator and guideline — cvdcheck.org.au. Work through several examples using the calculator yourself.
  • RACGP Red Book, 10th edition — the cardiovascular and preventive activities sections are heavily examined.
  • Therapeutic Guidelines: Cardiovascular and the Australian Medicines Handbook — the standard references for drug choice and dosing in the AKT and KFP.
  • National guide to preventive healthcare for Aboriginal and Torres Strait Islander people (RACGP/NACCHO).
  • Heart Foundation hypertension guideline 2016 (and the 2027 guideline once published).
  • RACGP check units on hypertension and cardiovascular risk, and relevant Australian Journal of General Practice articles.
  • Australian Prescriber — practical reviews of CVD risk and antihypertensive therapy.
  • Murtagh’s General Practice, 8th edition — chapter on hypertension.
  • RACGP curriculum and syllabus for Australian general practice — cardiovascular health unit, to check coverage.

Version history

VersionDateChanges
2026–27 (v1.5)10 Nov 2026Worked cases rewritten in the KFP multiple-selection format (from the 2025.2 sitting): standalone scenarios, one question each, “Select N from the following list”, with self-scoring.
2026–27 (v1.4)10 Nov 2026Study-priority stars (1–4) added to every section and subsection, with a star key and a “short on time” fast path to the must-know sections. Flashcards moved to the end of the lesson and shown on the page (no pop-up). Edition and date labels removed from the trainee view.
2026–27 (v1.3)10 Nov 2026Added 10-card flashcard pop-up; next-step buttons now open the flashcards and link to the cardiovascular chapter deck.
2026–27 (v1.2)10 Nov 2026Engagement layer added: cold-start check, old-notes check, exam-report pitfalls, selectable questions with confidence rating and score, exam-pace challenge, readiness checklist, revision plan and flashcard links.
2026–27 (v1.1)9 Nov 2026Self-check questions rewritten at AKT difficulty (10 items, length-matched options).
2026–27 (v1.0)9 Nov 2026First edition. Based on 2023 CVD risk guideline, 2016 Heart Foundation hypertension guideline, PBS fixed-dose combination change (Apr 2026), draft 2027 hypertension guideline consultation noted.

© GP Institute of Australia. For educational use by enrolled candidates only; not for redistribution. This lesson summarises Australian guidelines for exam preparation and does not replace current clinical guidelines or clinical judgement. Always check doses and PBS restrictions in current Therapeutic Guidelines, AMH and the PBS Schedule.

Sorry, You cannot copy contents of this page.

If you are trying to login, please use the right click to enter you details!

Scroll to Top